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Abstract
We investigated the ability of several principal components analysis (PCA)-based strategies to detect and control for
population stratification using data from a multi-center study of epithelial ovarian cancer among women of European-
American ethnicity. These include a correction based on an ancestry informative markers (AIMs) panel designed to capture
European ancestral variation and corrections utilizing un-thinned genome-wide SNP data; case-control samples were drawn
from four geographically distinct North-American sites. The AIMs-only and genome-wide first principal components (PC1)
both corresponded to the previously described North or Northwest-Southeast axis of European variation. We found that the
genome-wide PCA captured this primary dimension of variation more precisely and identified additional axes of genome-
wide variation of relevance to epithelial ovarian cancer. Associations evident between the genome-wide PCs and study site
corroborate North American immigration history and suggest that undiscovered dimensions of variation lie within Northern
Europe. The structure captured by the genome-wide PCA was also found within control individuals and did not reflect the
case-control variation present in the data. The genome-wide PCA highlighted three regions of local LD, corresponding to
the lactase (LCT) gene on chromosome 2, the human leukocyte antigen system (HLA) on chromosome 6 and to a common
inversion polymorphism on chromosome 8. These features did not compromise the efficacy of PCs from this analysis for
ancestry control. This study concludes that although AIMs panels are a cost-effective way of capturing population structure,
genome-wide data should preferably be used when available.
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Introduction
Genome-wide association studies (GWAS) have become an
essential tool for discovering genetic predisposition to complex
disease [1–4]. The validity of GWAS can be influenced by
improper control for inherited disease-associated genome-wide
background variation. Population stratification (PS) refers to
genome-wide patterns of linkage disequilibrium (LD) that, when
associated to the disease, can obscure the signal (present or absent)
of individual SNPs [5–9].
Although the confounding effect of population stratification has
been acknowledged, it has been considered to be of practical
concern primarily in admixed or mixed populations with ancestry
from different continents [10,11]. Despite this, some authors have
shown that even within the relatively more homogenous popula-
tion of European Americans, genome-wide structure can still be a
problem for association studies [12–15].
Panels of SNPs have been designed to specifically detect and
control for population stratification in European Americans [14–
17]. Even though these studies have involved a variety of data sets
they have all described a common major axis of variation for
European ancestry consisting of a North or Northwest -
Southeastern cline. However, these studies differ in the number
of significant dimensions of variation, in the SNPs selected as
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e35235ancestry informative markers (AIMs), and in the number of AIMs
that they derive. Hence, deciding on the optimal panel for a
particular set of data is not straightforward.
These European AIM panels were designed with the objective
of providing a cost effective way of controlling for stratification
through the reduction of genotyping costs in candidate gene
studies and validation studies [12,17]. Despite this, they may also
be used in genome-wide association studies (GWAS). Although a
principal component analysis (PCA) can be conducted on the
entire GWAS data set in order to control for ancestry [18],
restricting the analysis to AIMs can provide a way of avoiding the
effects of local LD patterns on the PCA results and a way to
prevent capturing and controlling away the case-control variation
of interest.
This study compares the performance of controlling for PS
through PCA using the Paschou et al. AIMs panel [17] data
(Paschou PCA) and using the genome-wide data (GWAS PCA) on
an ovarian cancer case control data set of European Americans
from four different North American sites. In particular, we
investigate the effects of capturing case-control variation and
regions of high local LD on the GWAS PCA based PS adjustment
strategy.
Methods
Details of the ovarian cancer GWAS are published [19]. Briefly,
the GWAS Stage I data we utilize here derive from four case-
control studies of epithelial ovarian cancer: the Mayo Clinic
Ovarian Cancer Study (MAYO, n=877) (Rochester, MN), which
includes residents of the six-state surrounding region (MN, IA, WI,
IL, ND, SD), Duke University’s North Carolina Ovarian Cancer
Study (NCO, n=1147) (Durham, NC), which includes residents of
a surrounding 48 county region, the University of Toronto
Familial Ovarian Tumor Study (TOR, n=1275) (Ontario,
Canada), and H. Lee Moffitt Cancer Center and Research
Institute’s Tampa Bay Ovarian Cancer Study (TBO, n=396)
(Tampa, FL), which includes residents from the surrounding 2
county region. All participants self-reported to be of European
non-Jewish ancestry. To increase etiologic homogeneity, we
excluded cases with non-epithelial or borderline tumors, known
BRCA1 and BRCA2 mutation carriers and women with a prior
history of ovarian, breast, endometrial, or early-onset colorectal
cancer. All controls had at least one ovary intact at the reference
date and were frequency-matched to cases on age-group. The
study protocol was approved by the institutional review board at
each center (by the IRBs at Mayo Clinic, at Duke University, at
the University of Toronto, and at the Lee Moffitt Cancer Center)
and all study participants provided written informed consent.
Blood served as the source of genomic DNA. All samples were
genotyped using the Illumina Infinium 610K Array and Illumina’s
Genome Studio
TM software was used to perform automated
genotype clustering and calling. After the quality control described
in Permuth Wey et al [19], a sample size of 3,715 subjects (1,815
cases and 1,900 controls) with 559,179 markers was available for
analysis.
Principal Component Analyses (PCA)
PCA was performed on 4 sets of markers: (1) The Paschou
European AIMs panel (Paschou PCA), (2) all available GWAS
markers from the Illumina 610K array genotyped in this study
(GWAS PCA), (3) all available markers using controls only (GWAS
control PCA) and (4) all available markers with removal of markers
in high LD regions (GWAS LD PCA), using the snpMatrix
package in R software [20].
Given a data matrix X with N individuals in the rows and P
SNPs in the columns, we calculated the eigenvalues and
eigenvectors of the N by N matrix, XX
T. The eigenvectors
correspond to the PC scores (S) which can then be used to
calculate the loadings (B) of the SNPs for each PC through
multiplication with the diagonal matrix of the eigenvalues (V):
B~XTSV
{ 1
2

:
For GWAS control PCA, the controls only were used to obtain
B and then the PC scores are obtained through multiplying the
entire data set to these loadings (X
TB). Only the first 10
eigenvalues are retained throughout these calculations.
Removal of Outliers
19 controls that were more than six standard deviations away
from the mean score for the PC for any of the first 10 PCs were
identified as outliers in GWAS control PCA. An additional case
individual was identified as an outlier in the GWAS PCA. All 20
individuals were removed from all PCAs based on the genome-
wide data. 1881 controls and 1814 cases were left from the original
data set of 1900 controls and 1815 cases, for a total of 3695
individuals.
Removal of LD Regions
The LD regions were defined by visually inspecting the loadings
plots for the individual PCs and identifying two SNPs that
bracketed the peak in its entirety. All SNPs within this region were
removed with the exception a central SNP with an extreme
loading, also identified through the plot. Out of the 559,179 SNPs
available in the GWAS data, 553,601 were retained for the GWAS
LD PCA.
Association Tests
The tests of association of each individual SNP to ovarian
cancer were conducted using a generalized linear model that
included PCs as covariates with the SNP effect modeled as an
ordinal (log-additive) genotypic effect. The inflation factors were
estimated by the ratio of the observed trimmed mean to its
expected value under the chi-squared assumption. Association
tests of the PCs to site and disease were conducted via multiple
linear regression implemented in R. Each PC was regressed on
disease status and site.
MLE and Price et al.’s AIMs Panel
In additon, maximum likelihood estimation was used to
determine estimates for Northwestern European, Southeastern
European and Ashkenazi Jewish ancestry based on an additonal
European AIM panel by Price et al [16].
Results
Principal Components
We compared the GWAS and Paschou PCs on the basis of their
correlations to one another, their associations with disease
controlling for site and their impact on inflation factor, where
we relied on their association to site as proxy for their relevance to
ancestry. The correlation between the first PCs (i.e PC1) of the
Paschou PCA and the GWAS PCA was 0.79. This first PC
corresponded to the Northwest-Southeast axis of variation that the
Paschou et al panel was solely designed to capture. A separate
analysis using Price et al’s panel confirmed this (see figure 1) [16].
European Stratification and Ovarian Cancer Data
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significant p-values (see table 1) and corrected for the inflation
factor better than Paschou PC1 (see table 2). Likewise, once site
differences were taken into account, only GWAS PC1 provided
evidence of an association between the first axis of European
American ancestral variation and ovarian cancer.
GWAS PCA also captured additional ancestral structure.
GWAS PC2 in figure 1 shows structure within individuals with
Northwestern ancestry that is not apparent in Paschou PC2. The
screeplots for both PCAs (see figure S1) showed that in contrast
to the Paschou PCA where only PC1 clearly lies before the
elbow in the plot, a criterion often used to infer that the variance
explained by the PC is greater than that expected by chance, the
GWAS PCs only began to level off at about the 20
th PC. This
additonal structure was corroborated by exploring the first 100
PCs and their association to site. Including all pairwise site
comparisons, the greatest significance was restricted to the first
20 PCs (see figure S2). Narrowing the analysis to the first 10 PCs,
only PCs 1,3 and 4 were significantly associated to both site and
ovarian cancer (see figure 2), while PC2 was not associated with
site or ovarian cancer. This suggests that PCs 1, 3 and 4 may all
account for dimensions of ancestral variation that have the
potential for confounding ovarian cancer case control association
testing. The effect of retaining the first 4 PCs on the inflation
factor also supports this finding since the inflation factor was
considerably lower than when using only GWAS PC1 or even
the first 10 PCs (see figure 3).
GWAS Control
The fact that GWAS PC1 is more strongly associated to ovarian
cancer than Paschou PC1 and that it produces a more effective
reduction in inflation factor may lead one to believe that GWAS
PC1 may be capturing case control variation and reducing power
of the GWAS. The same could be argued for the additional PCs
associated to ovarian cancer. In order to test this, we conducted a
PCA using only the control individuals (GWAS control PCA) in
which values of the case PCs were obtained as described in
Methods.
Although PCs 1 and 2 of GWAS control PCA were very highly
correlated to their counterparts in GWAS PCA (r.0.9), PCs 3
and 4 were also correlated, albeit to a lesser degree (r.0.6, see
table 3). A linear combination of GWAS control PCs 3 and 4
explained 68.9% of the variation in GWAS PC 3 and 68.7% of the
variation in GWAS PC 4, hence there was a redistribution of the
variance of GWAS PCs 3 and 4 across several of GWAS control’s
PCs.
Figure 1. Comparison of Paschou and GWAS PCAs. Blue, green and red points represent individuals with the highest estimates of north-
western, south-eastern and Ashkenazi Jewish ancestry respectively taken from MLE analysis with Price et al. AIMs panel.
doi:10.1371/journal.pone.0035235.g001
Table 1. Association of PC1 from Paschou and GWAS PCAs on site and disease status.
Paschou PC1 GWAS PC1
Estimate P-value Estimate P-value
Intercept 0.27 6.04e210 20.00660 1.99e212
NCO 20.27 9.97e207 0.00448 7.16e210
TBO 20.62 ,2e216 0.01023 ,2e216
TOR 20.30 3.17e208 0.00480 2.29e211
Disease 20.48 0.237 0.00165 0.00223
The intercept corresponds to the MAYO site.
doi:10.1371/journal.pone.0035235.t001
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adjusting for GWAS control PCs show the same pattern as those
obtained when adjusting for GWAS PCs, but are systematically
lower, indicating that the former provide a less effective correction
for PS. In both cases the inflation factor was considerably reduced
by PCs 1, 3 and 4. If the latter achieved this by capturing case
control variation, these axes of variation would not have been
identified in the PCA using only the controls. The smaller
reductions to the inflation factor observed for the GWAS control
adjustments is likely due to the GWAS control PCA’s smaller
sample size (n=1814 vs. n=3695). The reduction in the inflation
factor achieved by adding GWAS control PC5 may be explained
by its correlation (r=0.3) to GWAS PCA PC3.
Next, we compared the effects of adjustment for the first 4 PCs
of the two genome-wide PCAs on the p-values for SNP
associations to ovarian cancer. If the GWAS PCA were capturing
case-control variation, the strength of association of the top ranked
SNPs from the GWAS control adjusted analysis would be reduced
or controlled away by GWAS PCA adjusted analysis. Instead, we
observed that the most significant SNPs in the GWAS control PC
adjusted analysis remained the most significant SNPs in the
GWAS PC adjusted analysis (see the right panel of figure 4).
Figure 4 also shows that GWAS corrected for the top hits in the
same manner as GWAS control. The SNPs whose p-value changed
the most when compared to an uncorrected association test are
highlighted in red. The SNPs that cross the identity line from the
left panel to the right panel are those whose strength of association
is corrected in the same direction by the two sets of PCs and whose
correction is stronger using the GWAS PCs. SNPs that are more
distant from the identity line in the right panel than the left that
don’t cross it are those whose strength of association changes in a
different directions when adusting for one set of PCs versus the
other. Three out of the six SNPs that changed the most when
adjusted for the GWAS control PCs were more effectively
corrected by the GWAS PCs. One SNP received about the same
level of correction and two were corrected in the same direction
but not by as much in the GWAS adjusted analysis as in GWAS
control adjusted analysis. None of the SNPs were corrected in
different directions between the two sets of analyses.
Figure 2. Association to site and to disease controlling for site of first 10 PCs in GWAS PCA. P-values for all pair-wise comparisons among
four sites are given.
doi:10.1371/journal.pone.0035235.g002
Table 2. Inflation factors in genomewide ovarian cancer association testing before (uncorrected) and after controlling for
cumulative PCs from GWAS PCA, Paschou PCA, GWAS control PCA and GWAS LD PCA.
Uncorrected 1.059079
PC1 PC1 PC1 PC1
Paschou 1.051117 – – –
GWAS control 1.048420 1.048260 1.048863 1.042712
GWAS LD 1.045711 1.037447 1.038001 1.037692
GWAS 1.045605 1.045944 1.040444 1.036508
doi:10.1371/journal.pone.0035235.t002
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comparison of the genome-wide correction for the two PCAs can
also be made. The correlation between the p-values for all the
SNPs between the uncorrected association tests and those
corrected through GWAS PCA was 0.922, between the uncor-
rected and GWAS control was 0.958 and between the GWAS and
GWAS control PCAs was 0.983. If GWAS PCA were picking up
on genome-wide case control variation, and therefore correcting in
a qualitatively different way to GWAS control, its resultant p-
values would have been more closely correlated to the uncorrected
analysis rather than to those of GWAS control.
Linkage Desequilibrium
Plots of the individual SNP loadings for GWAS PCs 1 through 4
highlight three regions of high local LD. These appear as peaks on
chromosomes 2, 6 and 8 (see figure 5). These same regions were
apparent for the GWAS control PCs. These plots reveal that the
axes of variation defined by PCs 3 and 4 of the GWAS and GWAS
control PCAs are interchanged, with GWAS control PC3 showing
the pronounced peak on chromosome 8 that is evident in the plot
of GWAS PC4.
Figure 4. Top hits for ovarian cancer association. Negative log p-values of top hits for ovarian cancer association after controlling for ancestry
using first 4 PCs of GWAS control PCA compared to not controlling for ancestry (left panel) and controlling for ancestry using first 4 PCs of GWAS PCA
(right panel).
doi:10.1371/journal.pone.0035235.g004
Figure 3. Comparison of effect on the inflation factor l of
controlling for ancestry. The first 10 PCs obtained through Paschou
PCA, GWAS control PCA, GWAS PCA and GWAS LD PCA are used as
covariates in testing genome-wide association to ovarian cancer. Note
that the Paschou panel was designed to capture only one significant
PC.
doi:10.1371/journal.pone.0035235.g003
Table 3. GWAS PCA is compared to Paschou PCA, GWAS
control PCA and GWAS LD PCA.
GWAS
PC1 PC2 PC3 PC4
Paschou PC1 0.793 – – –
GWAS control PC1 0.949 – – –
PC2 – 0.936 – 0.116
PC3 – – 0.695 0.553
PC4 – – 0.461 0.612
GWAS LD PC1 0.984 0.138 – –
PC2 – 0.158 0.863 0.449
P C 3 ––––
P C 4 ––––
Correlations to the GWAS PCs that are greater than 0.1 are shown for the first 4
PCs.
doi:10.1371/journal.pone.0035235.t003
European Stratification and Ovarian Cancer Data
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peak on chromosome 2 corresponds to a region that contains SNP
rs4988235. This SNP is a known polymorphism in the gene LCT,
associated with lactase persistence. This SNP’s T allele is
associated with the North-South cline within Europe with a
frequency of 5–10% in southern Europe and 70–80% in northern
Europe [21]. The peak on chromosome 6 corresponds to the
major histocompatibility complex region (HLA), a well known
region with high LD [22]. GWAS PC2 loadings also have a
pronounced peak in the HLA region. PC3 and PC4 loadings have
peaks on chromosome 8 in a region with a polymorphic inversion
previously documented in European Americans [23225]. Al-
though the HLA and inversion regions appear to be more densely
sampled in the Illumina genome-wide SNP panel than other
regions of these chromosomes, this alone does not account for the
magnitude of the peaks (see table 4). In particular, chromosome 8
contains 7 other regions of the same size or smaller than the
inversion region that are similarly or more densely sampled by
SNPs in the panel, while the first 1 k SNPs that comprise the peak
in the HLA region have the same average density as the rest of
chromosome 6.
While there was evidence of ovarian cancer relevant structure in
the data in GWAS PCs 1 through 4, their loadings plots showed
that local LD may underlie this structure. We conducted an
additional PCA (GWAS LD PCA) in which only the SNP with the
highest loading was retained to represent each of the LD regions
(see table 4) to determine whether these regions affect the ability of
these PCs to correct for disease relevant PS.
The GWAS PC1, PC3 and a fraction of the GWAS PC4 axes of
variation were largely retained by the GWAS LD PCA, while the
PC2 axis of variation is lost (see table 3). GWAS LD PC2 captures
variation described by both of GWAS PCs 3 and 4. Hence the
chromosome 2 LCT gene and chromosome 8 inversion regions
appear to be correlated to ancestral components of the European
American population represented by GWAS PCs 1, 3 and 4. In
contrast, the GWAS LD PCA provides evidence that the HLA
region is not significantly associated with genome-wide European
ancestry PS. A large fraction of the variation described by GWAS
PC2 may therefore be local rather than genome-wide, ancestral
variation. This may account for its lack of association to site.
Thinning GWAS PCA LD regions resulted in less effective
control of the inflation factor (see figure 3). Only the first 2 PCs of
GWAS LD, which roughly correspond to GWAS PCs 1, 3 and 4,
lowered the inflation factor. PC1 reduced the inflation factor to the
same extent with and without thinning of SNPs at the LCT LD
region, while adjusting for PCs 3 and 4 reduced the inflation factor
more when the chromosome 8 LD region was not thinned.
Ancestral GWAS PCs and Association to Study Site
GWAS PCs 1, 3 and 4 are each highly significantly
associated with study site after adjustment for case-control
status (see table 5). Each PC identifies a distinct contrast
between the sites. The Mayo site (MAYO) has the lowest PC1
values and Tampa (TBO) the highest, on average; Toronto
(TOR) and North Carolina (NCO) are intermediate and not
discernably different. The sites have distinct mean values of
PC3 after adjustment for case-control status, and are ordered
(from smallest to largest value) NCO, TOR, TBO then MAY.
PC4 contrasts MAY and the remaining sites which are not
discernably different from one another.
A plot of PC1 against PC3 shows that variation represented by
PC 3 was within individuals of Northwestern European ancestry
(see figure S3). It also shows that PC 3 clearly varies across sites.
Not only did MAYO show a trend towards more positive PC 3
values compared to the other sites, but NCO showed a narrower
range variation for this PC compared to the other sites. PC 1
showed TBO to be the site with more of a representation of
Southeastern Europeans while MAYO had the least.
Discussion
Even though the information provided by all the SNPs
genotyped on a genome-wide panel can be used to control for
population structure via PCA, using a smaller predesigned AIMs
Figure 5. Loadings for the first 4 PCs. GWAS PCA (left panel) and GWAS control PCA (right panel) loadings are plotted showing peaks on
chromosome 2, 6 and 8.
doi:10.1371/journal.pone.0035235.g005
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controlling for stratification using the GWAS data may undesir-
ably reduce the case-control variation that the study seeks to
identify, while the chance that an AIMs panel will include disease
associated SNPs is remote. Secondly, corrections based on un-
thinned GWAS data may highlight local structure in place of
genome-wide, ancestral variation and, hence, compromise the
effectiveness of control for PS. AIMs panels deliberately exclude
redundancies between SNPs and therefore avoid this problem.
These potential disadvantages of GWAS-based corrections may be
compounded in populations with more subtle genome-wide
structure and stronger patterns of local LD such as the European
American population.
We found that these drawbacks were not realized in our
analysis of the ovarian cancer GWAS data. In particular, we
found that a full GWAS PCA recapitulated structure present
within the control individuals and was therefore not capturing a
significant amount of case-control variation. This is not
surprising since case-control variation, both genome-wide and
local, will seldom be large enough to overtake genome-wide
sources of population variation in a PCA. This and the
significantly reduced inflation factors compared with those
achieved using the Paschou panel suggests that the association
to ovarian cancer found for GWAS PCs 1, 3 and 4 represent a
real correction for PS even after accounting for site, one that is
likely due to the greater precision afforded by using the entire
GWAS data set. Note that only 460 of the Paschou panel’s 500
markers were available to us in the ovarian cancer GWAS data
set, thus reducing its power somewhat. However, this will often
be the case when using a pre-designed AIMs panel for
population structure control in a GWAS analysis.
Potential pitfalls of not taking into account the effect of regions
of high local LD on controlling for PS using PCA can be classified
into two case scenarios:(1) the functional variant lies outside of
these regions; in this case PCs that only represent variation in these
regions will not effectively control for PS, i.e. the inflation factor is
not sufficiently lowered, and (2) the functional variant lies within
such a region; in this case the PCs that strictly represent the local
structure of that region may control away the association, i.e. the
inflation factor is lowered too much. Although in this study the
regions of high local LD changed the results of the GWAS PCA,
the practical implications of this on testing SNP association to
ovarian cancer were questionable.
Only GWAS PC2 qualified as an example of this first
phenomenon. Its disappearance in GWAS LD PCA and its lack
of impact on the inflation factor and association to disease show
that it is primarily representing local structure in the HLA region
and suggests that functional variants are unlikely to lie within that
region. Even though the HLA LD region contained enough
Table 5. Association of PCs 1, 3 and 4 from GWAS PCA to site.
PC1 PC3 PC4
Estimate P-value Estimate P-value Estimate P-value
Intercept 20.00660 1.99e212 0.00397 1.77e205 20.00084 0.369
NCO 0.00448 7.16e210 20.01056 ,2e216 0.00557 3.03e214
TBO 0.01023 ,2e216 20.00626 1.26e210 0.00500 4.39e207
TOR 0.00480 2.29e211 20.00802 ,2e216 0.00526 3.15e213
Disease 0.00165 0.00223 0.00184 0.00052 20.00217 6.34e205
The intercept corresponds to the MAYO site.
doi:10.1371/journal.pone.0035235.t005
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including this PC when controlling for stratification is not very
different from that of including any number of non-informative
PCs when routinely taking the first 10 PCs as covariates (see
figure 3). Which of the high ranking PCs to include as covariates in
the association analysis and how many of them to include may
have more of an impact on inflation factor control than removing
the effects of LD regions on the PCA.
We did not observe an example of the second phenomenon
noted above in this data set. Instead, the axes of variation
described by the PCs that were found to be associated with disease
(GWAS PCs 1, 3 and 4) were retained to a considerable extent
when the regions of high local LD were thinned. This suggests that
although these PCs show high correlation to local LD regions and
these regions can potentially harbor functional variants, the PCs
represent real, ancestral, genome-wide structure and not just
variation within the LD region.
Using schizophrenia GWAS data on European Americans, Zou
et al. found the same LD regions as the current study, and an
additional peak on chromosome 17. Using a shrinkage method to
control for LD effects in PCA, they found that all peaks disappear
with the exception of the LCT region peak. They conclude that it
is important to account for LD when using PCA to control for PS
[25]. They did not provide the correlations between the PCs with
and without their shrinkage method. It is plausible that, as in the
current study, the two sets of PCs 3 and 4 are highly correlated
and that the polymorphic inversion region does not have a
practical effect on ancestry control.
Population stratification will vary from study to study depending
on the characteristics of the study population and the disease and it
may therefore be argued that the results presented here are specific
to this study. However, populations of European ancestry such as
the one studied here are particularly homogeneous and case-
control or local LD variation will be less likely to overshadow
ancestral population variation when using un-thinned GWAS data
for PCA, in studies of less homogenous populations, such as those
that bring together subjects from different continental ancestries
and/or that focus on admixed populations. In conclusion, we
recommend that a careful analysis using PCA of the full data set be
performed prior to deciding how to control for PS. Use of PCs
from a full GWAS PCA may provide better control for PS and
result in a lower inflation factor. An additional benefit is that such
an analysis may aid discovery and removal of outliers and or
related individuals that may be missed through other quality
control/quality assessment procedures. In this study, the outliers
we removed significantly influenced the PCs from the original
GWAS control analysis and proved to contain related individuals
missed by earlier QC filters.
It should be pointed out that the Paschou panel did
remarkably well in capturing a great proportion of the PS for
such a small number of SNPs. In fact, in a more recent paper
the investigators behind the Paschou panel show that it is
possible to predict individual ancestry within Europe down to a
few hundred kilometers from the origin, using panels of 500 or
1,000 SNPs [26]. These panels are a great tool for cost-
effectively genotyping individuals with the purpose of PS
control. What this study wishes to underline is that despite this
effectiveness, in the presence of full GWAS data we should not
be tempted to solely rely on such a reduced number of SNPs
when conducting the PCA.
It is interesting to note that the association between GWAS
PCs 1,3 and 4 and disease persists even after taking into
account site differences (see table 5). Taking into account these
site differences removes that part of the spurious association
between disease and ancestry that is due to differences in the
relative numbers of cases and controls that were recruited across
sites coupled with even subtle differences in ancestry across sites.
What remains must then be caused by within site differences in
ancestral make-up between cases and controls due to sampling
variation. What is remarkable here is that this within site
difference in ancestry between cases and controls results in a
persistent significant signal when all the sites are pooled
together. This means that either the difference in ancestry
between cases and controls occurred in the same direction by
chance at each site or that this difference in ancestry was so
pronounced in one of the sites that it drowned what occurred in
the remaining sites. Another possibility is that the association
between disease and ancestry is not spurious but real, thereby
explaining its consistent direction in all sites. If this consistency
is found to be greater than that expected by chance, this could
be taken as evidence for a real association between European
ancestry and ovarian cancer. In this manner we will be
leveraging on our multi-site GWAS data to pursue the question
of whether this association is spurious or real in a future
publication. If real it would be of value to investigate whether
shared culture or other exposures such as parity or oral
contraceptive use explain this connection or whether genetic
variants underlie it and are potentially being missed due to
routine ancestry control in association testing.
Our findings confirm what is known about immigration history
of North America [27,28]. The first immigration wave corre-
sponded to the colonization by England and other European
countries and the last wave to the surge in Latin American
immigration of the last 50 years. The second and third waves of
immigration may explain the potential source(s) of the differences
found between these study’s sites. In the second wave, which
mainly consisted of northern Europeans such as Germans, Irish,
Danes, Swedes, Norwegians and Finns, immigrants bypassed the
East coast of the United States to settle the Northern Midwest.
This occurred because the Southern coastal states did not have
open land to settle, and, with the implementation of slavery the
supply of cheap labor from Europe was not as needed as in the
industrial Northern Midwest. In fact, before the third wave of
immigration only less than 0.25% of North Carolina’s population
consisted of immigrants [27]. The third wave of immigration
consisted mainly of individuals from Southeastern Europe, notably
Italy and Greece, Hungary and Poland [27,28].
Toronto is similar to the South coastal United States in that its
population was dominated by British citizens at the start of the
20
th century. It wasn’t until after WWII that Toronto became the
extremely diverse city it is with immigrants from all over the world
[29]. It would be expected then that the South coastal sites in this
study, North Carolina (NCO) and Tampa, Florida (TBO) would
have a combination of settlers from the first and third waves of
immigration, mainly Europeans from the British Isles and from
Southeastern Europe. Toronto would likewise have a dominance
of British ancestry. The Mayo Clinic site (MAYO) on the other
hand which consists of the Northern Midwest states, would instead
be expected to have a wider and different sampling of Northern
Europeans compared to all the other sites and relatively less
individuals from Southeastern Europe. In figure S3 MAYO
showed the smallest relative amount of Southeastern European
ancestry compared to all of the other sites (PC1 on horizontal axis)
and a different distribution of Northern European ancestry
compared to the other sites (PC 3 on vertical axis). The ancestral
variation that PCs 3 and 4 were accounting for must still be
confirmed in a future study that includes samples from delimited
regions in Northern Europe.
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Genome-wide data PCA allows for a detailed assessment of the
population structure present in the geographic region(s) being
studied as it is relevant to the disease phenotype in a way that a
specific AIMs panel based PCA cannot. Utilizing genome-wide
PCA data can also inform investigators about genomic regions in
LD that correlate to ancestry and disease and that are interesting
population features in themselves. Although AIMs panels are an
efficient cost-effective way of capturing population structure,
genome-wide data should preferably be used whenever it is
available.
Supporting Information
Figure S1 Screeplots for Paschou et al. AIMs PCA and
GWAS PCA.
(TIF)
Figure S2 Association to site of first 100 PCs in GWAS
PCA. P-values for each pair-wise comparison among the four sites
are given.
(TIF)
Figure S3 Scores for PCs 1 and 3 of GWAS PCA across
the 4 sites. TOR, TBO, NCO and MAYO individuals are
highlighted in blue in the respective panel.
(TIF)
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